Use of Macrolides in Acute Chest Syndrome: A Multicenter Retrospective Study

This study looks at whether using macrolide antibiotics is helpful and safe in treating acute chest syndrome, a serious complication in people with sickle cell disease. It reviews past cases from three hospitals where patients were treated in intensive care. The goal is to understand if macrolides make a difference, what germs are involved, how useful lab tests are, and how well patients tolerate these antibiotics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sickle Cell Disease Acute Chest Syndrome Anemia Anemia, Hemolytic Anemia, Hemolytic, Congenital Anemia, Sickle Cell Anti-bacterial Agents Carbohydrate Metabolism, Inborn Errors Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Glucose-6-Phosphate Dehydrogenase Deficiency Glucosephosphate Dehydrogenase Deficiency Hematologic Diseases Hemic and Lymphatic Diseases Hemoglobinopathies Lung Diseases Macrolides Metabolic Diseases Metabolism, Inborn Errors Nutritional and Metabolic Diseases Respiration Disorders Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

France

Saint-Denis, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patient (≥18 years old).
Diagnosis of acute chest syndrome (ACS).
Hospitalized in an intensive care unit (ICU).
Microbiological sampling performed (e.g., multiplex PCR, sputum culture [ECBC], and/or Legionella urinary antigen test).
Received empiric antibiotic therapy including a macrolide.

Exclusion criteria

Minor patient (<18 years old).
Acute chest syndrome not requiring ICU admission.
Acute chest syndrome without any attempt at microbiological documentation.

Treatment and study plan

Primary outcomes

Duration of mechanical ventilation (in days) among patients with ACS treated with empiric macrolides

Time frame: 28 days

Sponsors and collaborators

Lead sponsor

Centre Hospitalier de Saint-Denis

Other

Registry information

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Jun 25, 2025
Registry last updated: Jun 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed